Business
Inside information: Bioretec updates its strategy for 2026-2028 and provides new financial targets
As announced in September, Bioretec Ltd ("Bioretec" or the "Company") has assessed its overall commercialization strategy, pipeline, and options to accelerate growth. Bioretec's Board of Directors has today approved the Company's updated strategy for 2026–2028 and new financial targets for the strategy period.
About this update from Bioretec Ltd.
[{"type":"text","content":"Bioretec Ltd Inside information 16 December 2025 at 8:45 a.m. EET","length":65,"tagName":"p"},{"type":"text","content":"TAMPERE, Finland, Dec. 16, 2025 /PRNewswire/ -- As announced in September, Bioretec Ltd ("Bioretec" or the "Company") has assessed its overall commercialization strategy, pipeline, and options to accelerate growth. Bioretec's Board of Directors has today approved the Company's updated strategy for 2026–2028 and new financial targets for the strategy period.","length":387,"tagName":"p"},{"type":"text","content":"To support the execution of the new strategy, Bioretec is also currently assessing financing options.","length":101,"tagName":"p"},{"type":"text","content":"Bioretec's strategy for the period 2026–2028:","length":49,"tagName":"p"},{"type":"text","content":"Bioretec's strategy and value creation for the next three years focuses on commercial performance and sales acceleration in both the United States and markets outside of the United States (OUS), enabled by continued R&D and expansion of the RemeOs™ product family.","length":277,"tagName":"p"},{"type":"text","content":"The strategy is based on three pillars:","length":39,"tagName":"p"},{"type":"text","content":"Industry leading innovation: pioneering world class materials science by demonstrating patient outcomes that validate healing through the absorption of our materials.","length":166,"tagName":"p"},{"type":"text","content":"World-class clinical and economic evidence generation: expanding the patent portfolio for new and existing materials and research methods to build a sustained competitive market advantage.","length":188,"tagName":"p"},{"type":"text","content":"Global excellence in commercialization: accelerate our focus on high value repeatable business and collaboration with best-in-class partners globally to achieve market success.","length":176,"tagName":"p"},{"type":"text","content":"Strategic priorities for the period 2026–2028:","length":46,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Demonstrate industry leading innovation, clinical evidence generation, and commercial scale by progressing a strong R&D pipeline and introducing at least one new product or indication every 12–18 months, reflected by sustained R&D investments","length":250,"tagName":"p"}]},{"val"...